Regina Hodits

Atlas Venture LLP is the London office of the independent and partner-owned venture capital investment group Atlas Venture Inc., headquartered in Boston with additional offices in Paris and Munich, plus an administrative office in Amsterdam. The group originated in 1980 and focuses on high-technology financing, aiming for a transatlantic operations model. The London office was established in 1986. The group manages a range of venture capital funds.

Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland.

U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany.

Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action.

Lumavita AG is a specialty biopharmaceutical company dedicated to bring to market innovative anti-infectives for women's health. Based in Basel, Switzerland, Lumavita was recently financed by a syndicate, lead by Atlas Venture, with CHF18 million (EUR11 million). The company has one product under regulatory review in Switzerland and two further projects in clinical development.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

The German Private Equity & Venture Capital Association is the federal association of participation capital and serves as the voice of the participation capital industry. The private company is based in Berlin, Germany. The association analyzes the market and its constant development.

Sapiens Steering Brain Stimulation BV develops medical devices. The company was founded by Sjaak Deckers in 2011 and is headquartered in Eindhoven, the Netherlands.

Sapiens Steering Brain Stimulation GmbH develops and markets steering deep brain stimulation (DBS) solutions. The firm specializes in the research, design, and delivery of medical solutions to patients suffering from degenerative or functional brain disorders, such as Parkinson’s disease and dystonia. Its product offerings encompass micro-fabricated probes, neurostimulators, and the SureSuite technology, which act as a unified surgical procedure platform. Its SurePlan, SurePlace, and SureTune products provide an integrated and image-based solution for planning and programming an optimal DBS treatment. The company was founded by Sjaak Deckers, Michel Decré and Hubert Martens in 2011 and is headquartered in Munich, Germany.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom.

Middle Peak Medical, Inc. develops implants for treatment of mitral valve disease. Its technology has application in both percutaneous catheter-based intervention and in minimally invasive or open-heart cardiac surgery. The company was founded by Michael D. Lesh and Alexander Khairkhahan in 2011 and is headquartered in Palo Alto, CA.

Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany.

Tricares SAS commercializes medical device. The company was founded by Coralie Marchand and Pascal Lim on September 2, 2013 and is headquartered in Paris, France.

ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland.

Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France.

GoodlifeMe AB engages in the development of health games. It designs SidekickHealth, which is a social health game designed to engage users through health improvement and team building. The firm provides platform and app featuring programs for diet, physical activity, and stress management. The company was founded by Saemundur Jon Oddsson and Tryggvi Thorgeirsson and is headquartered in Gothenburg, Sweden.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

SNIPR Biome ApS develops bacterial composition to provide treatment for diabetes to cancer. The company was founded by Christian Grøndal and is headquartered in Kongens Lyngby, Denmark.

STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark.

NovaMed Pharmaceuticals Inc. engages in pharmaceutical preparations. It manufactures and distributes healthcare and pharmaceutical products. The company was founded by Mark Lotter, Min Geng Xiao and Bo Shao on August 1, 2005 and is headquartered in Shanghai, China.